Completed PHASE2 INTERVENTIONAL 4-arm NCT00955981

Gout Dose Response Study

Randomized, Double-Blind, Multicenter, Placebo-Controlled, Safety and Efficacy Study of RDEA594 Versus Placebo in the Treatment of Hyperuricemia in Patients With Gout

Sponsor: Ardea Biosciences, Inc.

Conditions Hyperuricemia

Interventions Placebo RDEA594

Updated 8 times since 2017 Last updated: Feb 5, 2014 Started: Jul 31, 2009 Primary completion: Mar 31, 2010 Completion: Sep 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Hyperuricemia, this trial is completed. The trial is conducted by Ardea Biosciences, Inc. and has accumulated 8 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ardea Biosciences, Inc.

Data source: Ardea Biosciences, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bruntál, Czechia , Coquitlam, Canada , DeLand, United States , Elblag, Poland , Goch, Germany , Hamburg, Germany , Jackson, United States , Kelowna, Canada , Lodz, Poland , Los Angeles, United States and 16 more locations